Abstract
Abstract
Background: Two novel HER2 aptamers were recently selected with great potential for the in vitro diagnosis of
HER2-positive cancer. The goal of this study was to examine the in vivo diagnostic potential of these HER2
aptamers.
Methods: Both HER2 aptamers were radiolabelled with 68Ga, injected in mice bearing a HER2-positive and
HER2-negative tumour and evaluated by PET/MRI.
Results: Ex vivo bio distribution analysis revealed high uptake in the blood, tissues and organs, except the brain.
Interestingly, this high uptake was explained by the slow blood clearance due to non-specific aptamer binding to
blood proteins. We observed accumulation of radioactivity in both tumours in time. Although higher uptake in the
HER2-positive tumour compared to the HER2-negative tumour was observed, this was accompanied with more
necrosis in the HER2-negative tumour, which was observed by 18FDG PET/CT.
Conclusion: This work presents a first step towards the development of 68Ga-labelled aptamers for molecular
cancer imaging.
Original language | English |
---|---|
Article number | 1000300 |
Number of pages | 8 |
Journal | Journal of Nuclear Medicine and Radiation Therapy |
Volume | 7 |
Issue number | 5 |
DOIs | |
State | Published - 11 Aug 2016 |